0000950170-24-001971.txt : 20240104 0000950170-24-001971.hdr.sgml : 20240104 20240104164038 ACCESSION NUMBER: 0000950170-24-001971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tregoning Kathleen CENTRAL INDEX KEY: 0001830764 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 24512687 MAIL ADDRESS: STREET 1: C/O CEREVEL THERAPEUTICS HOLDINGS, INC. STREET 2: 131 DARTMOUTH STREET SUITE 502 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 4 1 ownership.xml 4 X0508 4 2024-01-02 0001701108 Spero Therapeutics, Inc. SPRO 0001830764 Tregoning Kathleen C/O SPERO THERAPEUTICS, INC. 675 MASSACHUSETTS AVENUE, 14TH FLOOR CAMBRIDGE MA 02139 true false false false false Stock Option (Right to Buy) 1.52 2024-01-02 4 A false 35604 1.12 A 2034-01-02 Common Stock 35604 35604 D This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $40,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. /s/ Tamara Joseph, Attorney-in-Fact for Kathleen Tregoning 2024-01-04